A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That’s the world Volition is trying to build by developing its innovative family of simple, easy to use, cost-effective blood tests. Volition is a multi-national epigenetics company. It has patented technologies that use chromosomal structures, such as nucleosomes, and transcription factors as biomarkers in cancer and other diseases. The tests in the Company’s product portfolio detect certain characteristic changes that occur from the earliest stages of disease, enabling early detection and offering a better way to monitor disease progression and a patient’s response to treatment. The tests offered by Volition and its subsidiaries are designed to detect and monitor a range of life-altering diseases, including certain cancers and diseases associated with NETosis, such as sepsis.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 1.5M | - | - | - | - | - |
| Net Income | -44M | -27M | -35M | -31M | -27M | -20M |
| EPS | $-0.48 | $-0.31 | $-0.50 | $-0.55 | $-0.43 | $-0.45 |
| Free Cash Flow | -20M | -26M | -19M | -17M | -22M | -18M |
| ROIC | -278.1% | -227.1% | -101.7% | -137.2% | -10688.5% | -4874.4% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -0.16 | -0.46 | -1.08 | 0.17 | 0.21 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -23M | -27M | -36M | -32M | -28M | -21M |
| Operating Margin | -1542.2% | - | - | - | - | - |
| ROE | 0.0% | - | - | - | -152.3% | -124.8% |
| Shares Outstanding | 123M | 87M | 71M | 56M | 63M | 45M |
| Metric | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | 1.5M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -16M | -21M | -28M | -32M | -36M | -27M | -23M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | -1542.2% |
| Net Income | -16M | -20M | -27M | -31M | -35M | -27M | -44M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | -2997.1% |
| Non-Recurring | 0 | 0 | 0 | 0 | -16K | -35K | -35K |
| Returns on Capital | |||||||
| ROIC | -98.2% | N/M | N/M | -137.2% | -101.7% | N/M | N/M |
| ROE | -113.4% | -124.8% | -152.3% | N/A | N/A | N/A | 0.0% |
| ROA | -75.6% | -78.0% | -98.2% | -167.2% | -126.4% | -144.4% | -684.1% |
| Cash Flow | |||||||
| Op. Cash Flow | -13M | -16M | -21M | -15M | -18M | -26M | -20M |
| Free Cash Flow | -13M | -18M | -22M | -17M | -19M | -26M | -20M |
| Owner Earnings | -13M | -17M | -24M | -19M | -22M | -28M | -22M |
| CapEx | 511K | 1.9M | 974K | 1.6M | 1.1M | 277K | 0 |
| Maint. CapEx | 677K | 716K | 945K | 936K | 1.2M | 1.1M | 1.1M |
| Growth CapEx | 0 | 1.2M | 28K | 634K | 0 | 0 | 0 |
| D&A | 677K | 716K | 945K | 936K | 1.2M | 1.1M | 1.1M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 32K | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.1% | N/A | 0.0% |
| Stock-Based Comp | 0 | 187K | 2.5M | 3.1M | 2.3M | 1.3M | 1.3M |
| Debt Repayment | 0 | 0 | 0 | 1.3M | 981K | 1.1M | 1.1M |
| Balance Sheet | |||||||
| Net Debt | -14M | -16M | -18M | -7.0M | -16M | 1.5M | 6.3M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | 199K |
| Long-Term Debt | 2.2M | 2.6M | 2.3M | 2.8M | 3.6M | 4.0M | 4.0M |
| Debt/Equity | 0.20 | 0.21 | 0.17 | -1.08 | -0.46 | -0.16 | 0.00 |
| Interest Coverage | -126.7 | -163.7 | -181.9 | -183.6 | -162.4 | -79.4 | -79.4 |
| Equity | 14M | 16M | 18M | -2.6M | -7.8M | -25M | -35M |
| Total Assets | 21M | 26M | 27M | 18M | 28M | 9.4M | 6.4M |
| Total Liabilities | 7.1M | 9.9M | 9.8M | 21M | 36M | 34M | 42M |
| Intangibles | N/A | N/A | N/A | 221K | N/A | N/A | N/A |
| Retained Earnings | -90M | -110M | -137M | -167M | -203M | -230M | -230M |
| Working Capital | 14M | 14M | 15M | -5.2M | 13M | -3.7M | -3.7M |
| Current Assets | 18M | 20M | 22M | 12M | 22M | 4.1M | 4.1M |
| Current Liabilities | 3.9M | 6.2M | 6.5M | 17M | 8.9M | 7.8M | 7.8M |
| Per Share Data | |||||||
| EPS | -0.41 | -0.45 | -0.43 | -0.55 | -0.50 | -0.31 | -0.48 |
| Owner EPS | -0.34 | -0.38 | -0.38 | -0.35 | -0.30 | -0.33 | -0.18 |
| Book Value | 0.36 | 0.36 | 0.28 | -0.05 | -0.11 | -0.29 | -0.28 |
| Cash Flow/Share | -0.32 | -0.36 | -0.33 | -0.27 | -0.26 | -0.30 | -0.35 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 39.3M | 45.3M | 63.1M | 55.6M | 70.6M | 87.0M | 122.8M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -0.3 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 12.7 | 11.0 | 11.5 | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | 13.4 |
| FCF Yield | -7.3% | -10.3% | -10.7% | -13.1% | -41.1% | -48.5% | -100.1% |
| Market Cap | 181M | 180M | 203M | 129M | 47M | 54M | 20M |
| Avg. Price | 3.79 | 3.66 | 3.57 | 2.30 | 1.44 | 0.76 | 0.16 |
| Year-End Price | 4.60 | 3.96 | 3.22 | 2.32 | 0.66 | 0.62 | 0.16 |
VOLITIONRX LTD passes 0 of 9 quality checks, indicating weak fundamentals.
VOLITIONRX LTD (VNRX) has a 5-year average return on invested capital (ROIC) of -119.5%. This is below average and may indicate limited pricing power.
VOLITIONRX LTD (VNRX) has a market capitalization of $20M. It is classified as a small-cap stock.
VOLITIONRX LTD (VNRX) does not currently pay a regular dividend.
VOLITIONRX LTD (VNRX) operates in the In Vitro & In Vivo Diagnostic Substances industry, within the Healthcare sector.
VOLITIONRX LTD (VNRX) generated $-26 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
VOLITIONRX LTD (VNRX) reported earnings per share (EPS) of $-0.31 in its most recent fiscal year.
The Ledger Terminal provides 6 years of financial data for VOLITIONRX LTD (VNRX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
VOLITIONRX LTD (VNRX) has a book value per share of $-0.29, based on its most recent annual SEC filing.
No recent press releases.